[Pharmacological neuroprotection against brain damage in ischemiai/reperfusion experiment].
Experiment carried out on laboratory animals (rats) were aimed at comparative evaluation of the effect of several neuroprotective drugs under the conditions of model brain ischemia-reperfusion. The experimental methods included staining of brain tissue sections by hematoxiline-eosine, Nissl staining, and expression of NOS1, NOS3, TRAIL by imunnohistological means. The intensity of damage in various parts of brain and the nature of apoptosis without neuroprotection and with popular neuroprotectors (cytoflavin, actovegin, mexidol) and a test drug at the stage ofpreclinical trial (AKF-90-7) were evaluated. Characteristic cytotoxic (coagulative pycnomorphic and colliquative necrosis of neurons) and vascular (hemostasia, erythropedesis) changes were revealed. The neuroprotective effectof drugs decreases in the following order: AKF-90-7 > cytoflavin > actovegin > mexidol.
V I
VI
Petrov
É A
ÉA
Ponomarev
S S
SS
Maskin
N N
NN
Strepetov
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D004801:Eosine Yellowish-(YS) / Q000032:analysis; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000627:therapeutic use; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006416:Hematoxylin / Q000032:analysis; D006418:Heme / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects*; D007150:Immunohistochemistry; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D009336:Necrosis / Q000517:prevention & control; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use; D052248:Nitric Oxide Synthase Type I / Q000032:analysis / Q000096:biosynthesis; D052250:Nitric Oxide Synthase Type III / Q000032:analysis / Q000096:biosynthesis; D010847:Picolines / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D015427:Reperfusion Injury / Q000097:blood / Q000188:drug therapy*; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000032:analysis / Q000096:biosynthesis
D004338:Drug Combinations; C517200:N-acetylaminoacetic acid 3-dimethoxyphosphoryl-2-hydroxy-1-propyl ester; D018696:Neuroprotective Agents; D010847:Picolines; D013386:Succinates; D053221:TNF-Related Apoptosis-Inducing Ligand; C505655:Tnfsf10 protein, rat; C507879:cytoflavin; D009536:Niacinamide; C070020:emoxypine succinate; D006418:Heme; C015646:Actovegin; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D052248:Nitric Oxide Synthase Type I; D052250:Nitric Oxide Synthase Type III; C496322:Nos1 protein, rat; C496316:Nos3 protein, rat; D004801:Eosine Yellowish-(YS); D005998:Glycine; D006416:Hematoxylin